clinical trial · NCT07137494
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Primary Central Nervous System (CNS) LymphomaSecondary Central Nervous System LymphomaMB-CART19.1 Cellular Therapy
brief summary
This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.
started
Aug 14, 2025
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Apr 21, 2026
official title
A Phase I Study of MB-CART19.1 Cellular Therapy for Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL) Using On- Site Manufacturing With the CliniMACS Prodigy Device
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol